We have collected information about Sirna Therapeutics Delivery for you. Follow the links to find out details on Sirna Therapeutics Delivery.
https://www.nature.com/articles/nmat3765
Oct 23, 2013 · Therapeutics based on small interfering RNA (siRNA), which in principle are able to reversibly silence any gene of interest, are under development for the …Author: Rosemary Kanasty, Joseph Robert Dorkin, Arturo Vegas, Arturo Vegas, Daniel Anderson
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-017-0450-0
Jun 27, 2017 · In this review, we discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene/protein expression and genome editing that are currently being investigated both in the laboratory as ...Author: James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson
https://www.mdpi.com/journal/pharmaceutics/special_issues/drug_delivery_of_siRNA_therapeutics
After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery. Full article
https://www.ncbi.nlm.nih.gov/pubmed/31054052
Apr 30, 2019 · Herein, we highlight the breakthroughs in siRNA therapeutics, with special feature on the first FDA approved RNAi therapeutics Onpattro (Patisiran) and the consideration of effective siRNA delivery system focusing on current siRNA nanocarrier in clinical trials.Author: Phei Er Saw, Er-Wei Song
https://onlinelibrary.wiley.com/doi/full/10.1002/jgm.3097
56 rows · With this milestone achievement, siRNA therapeutics will soar in the coming years. Here, we …Author: Bo Hu, Yuhua Weng, Xin‐Hua Xia, Xing‐jie Liang, Yuanyu Huang, Yuanyu Huang
https://www.mdpi.com/1999-4923/12/2/178/pdf
This Special Issue of Pharmaceutics titled “Drug Delivery of siRNA Therapeutics” aims to present the state of the art of siRNA delivery, embracing investigation strategies of international research groups with di erent experiences and skills. The Special Issue will thus be devoted to presentingAuthor: Gaetano Lamberti, Anna Angela Barba
https://www.nature.com/articles/s41573-019-0017-4
Mar 07, 2019 · Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid. Ther. 28 , 109–118 (2018). This …Author: Ryan L. Setten, Ryan L. Setten, John J. Rossi, John J. Rossi, Si-ping Han, Si-ping Han
https://www.researchgate.net/publication/258036544_Delivery_materials_for_siRNA_therapeutics
Delivery materials for siRNA therapeutics. ... an introduction to the biological challenges that siRNA delivery materials aim to overcome, as well as a discussion of the way that the most ...
https://www.sciencedirect.com/science/article/pii/S2162253116300373
Delivery of siRNA and miRNA Therapeutics. While chemical modification can improve the stability and reduce off-target effects of siRNAs and miRNAs, poor delivery is still a major challenge in translating therapeutic siRNAs and miRNAs into the clinic.Author: Jenny K W Lam, Jenny K W Lam, Michael Y T Chow, Yu Zhang, Susan W S Leung, Susan W S Leung
Searching for Sirna Therapeutics Delivery?
You can just click the links above. The data is collected for you.
